Drug intelligence / Profile preview

OneCAR

Development stage: Preclinical
Lead developer: ARCE Therapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

OneCAR is a proprietary, next-generation allogeneic Chimeric Antigen Receptor (CAR)-T cell therapy developed by ARCE Therapeutics. It is designed as an "off-the-shelf" treatment, utilizing T cells derived from healthy donors. This approach aims to provide a universal, economical, safe, and readily available therapeutic option for cancer patients, addressing the limitations of patient-specific autologous CAR-T therapies. OneCAR is characterized by its universal design to mitigate allogeneic immune rejection, potential for mass production to reduce costs, enhanced safety profile, and immediate availability for use.

Brand names: OneCAR

Targets

Tumor-associated surface antigen recognized by OneCAR scFv

Beyond the preview

Go deeper on OneCAR.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OneCAR.

Explore the full profile